Background: Differences in drug response among patients are common. Most major drugs
are effective in only 25 to 60 percent of the patients, in part due to the CYP enzymes, whose …

Since the term 'polymorphisms' entered clinical circles, many trials have begun to elucidate
the possible relationship between drugs and side-effects. An increasing number of articles …

The polymorphic nature of the cytochrome P450 (CYP) genes affects individual drug
response and adverse reactions to a great extent. This variation includes copy number …

Aims Although substantial progress has been made in understanding of ontogeny of drug
metabolism, there is still a gap of knowledge in developmental pharmacogenetics in …

Aim: The present study aimed to investigate the human genetic diversity of the CYP450
superfamily in order to identify functional interethnic differences and analyze the role of …

Pharmacogenetics (or pharmacogenomics) studies the role of inherited and acquired
genetic variation in drug response. Clinically relevant pharmacogenetic examples, mainly …

To improve the modeling and simulation of pharmacokinetics in pediatric patients, research
into developmental and disease-specific determinants is needed. This article describes the …

Cytochromes P450 are members of a superfamily of hemoproteins that catalyze a variety of
oxidative reactions in the metabolism of endogenous and exogenous hydrophobic …

Background: Data on the frequency of pharmacogenetic polymorphisms in the Croatian
population are limited. We determined and analyzed frequencies for the most important …

Cytochrome P450 3A (CYP3A) subfamily enzymes are involved in the metabolism of 40% of
drugs in clinical use. Twin studies have indicated that 66% of the variability in CYP3A4 …